Continued strong commercial execution of the OGSIVEO launch in the U.S. with fourth quarter and full-year 2024 U.S. net product revenue for OGSIVEO of $61.5 million and $172.0 million, respectively.
MUNICH, Germany, and BASILDON, UK I February 13, 2025 I LINDIS Biotech GmbH, a clinical stage biopharmaceutical company with a proprietary multi-specific ...
The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis' ...
New EU regulations aim to speed up health technology assessments (HTAs), but the pharma industry raises logistical concerns.
The approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in ...
From 2018 to 2020, he served as Chief Commercial Officer at Omeros Corporation, overseeing U.S. and EU launch readiness for narsoplimab ... for which we have obtained FDA and European Medicines Agency ...
CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars:  On January 30, 2025, the European Medicines Agency (EMA) Committee ...
The EU and its member states are committed to spending more and better together on defence in response to the unprecedented threats and security challenges that Europe is currently facing. Between ...
BRUSSELS — Keir Starmer has told the European Union to “step up” when it comes to supporting Ukraine ahead of a meeting with EU leaders to talk security. Speaking at a joint press conference with NATO ...
Speaking before an informal meeting to discuss security issues, European leaders appeared to agree that the EU will fight US tariffs, if they were to be applied. German chancellor Olaf Scholz said ...